Search

Additionally, occurrence of both AD eyelid involvement and AD facial involvement in the past year was significantly higher in patients with moderate-to-severe OSD compared to patients with no or mild OSD ( I n i = 28 (90.3%) vs. I n i = 18 (46.2%), I p i = <.001 and I n i = 31 (100.0%) vs. I n i = 33 (84.6%), I p i = .030 respectively). Keywords: atopic dermatitis; goblet cell; ocular surface disease EN atopic dermatitis goblet cell ocular surface disease 801 805 5 06/01/22 20220601 NES 220601 Key Messages In a single-centre study, we assessed ocular surface disease prevalence in moderate-to-severe atopic dermatitis. Diagnosing OSD is important since it may be associated with chronic limbitis, possibly leading to irreversible limbal stem cell deficiency and subsequently to irreversible long-term visual loss.3 In our study, lower conjunctival GCD was found in patients with OSD, compared to patients without OSD. However, by comparing GCD of patients with OSD to GCD of healthy controls described in the literature, we can conclude that moderate-to-severe AD patients with OSD have lower GC counts. [Extracted from the article]

This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis in a large prospective daily practice cohort. Data from the Dutch BioDay Registry were used to assess the risk of developing dupilumab-associated ocular surface disease, by performing univariate and multivariate logistic regression analyses. A total of 469 patients were included, of which 152/469 (32.4%) developed dupilumab-associated ocular surface disease. Multivariate analysis showed a statistically significant association of the development of dupilumab-associated ocular surface disease with a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at the start of dupilumab (odds ratio 5.16, 95% confidence interval 2.30-11.56, p < 0.001). In conclusion, a history of any eye disease (history of self-reported episodic acute allergic conjunctivitis excluded) combined with the use of ophthalmic medication at baseline was associated with the development of dupilumab-associated ocular surface disease in patients with atopic dermatitis. [ABSTRACT FROM AUTHOR]

Median goblet cell density was 2.6 cells/mm (IQR 1.1-4.0) in patients compared to 4.1 cells/mm and 9.8 cells/mm in HCs (Table S1b). Conjunctival inflammation in dupilumab-treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study Composite images derived from Imaging Mass Cytometry of conjunctival biopsy samples from AD patients developing conjunctivitis during dupilumab treatment. [Extracted from the article]

Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7-780.8)) to week 52 (€0.0 (0.0-211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice. [ABSTRACT FROM AUTHOR]

Introduction: Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce. Objective: To study the effect of 16‐week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate‐severe AD in daily practice. Methods: Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen‐week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI‐50 (Eczema Area and Severity Index) or EASI‐75, as well as patient‐reported outcomes measures (Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty‐one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks). Results: In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult‐to‐treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI‐50 and EASI‐75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity‐related serum biomarkers (TARC, PARC, periostin, and IL‐22), eotaxin‐1, and eotaxin‐3 significantly decreased. Conclusion: Treatment with dupilumab significantly improved disease severity and decreased severity‐related serum biomarkers in patients with very difficult‐to‐treat AD in a daily practice setting. [ABSTRACT FROM AUTHOR]

Combining these eight biomarkers in a biomarker signature increased the capacity to predict treatment responses in severe AD patients. Our results imply that pathophysiological heterogeneity in immunological pathways might underlie differences in treatment responses, and may be used to distinguish a specific subpopulation of difficult-to-treat AD patients in need of systemic treatment from patients who can be controlled with topical therapy. This signature might serve as a valuable addition to the decision whether to start systemic therapy or not in individual AD patients, and the statistical algorithm used in this study may also be applied to construct biomarker signatures predicting treatment response to systemic immunosuppressive drugs, dupilumab or other therapies in the future. Since more targeted therapies will play an increasingly important role in AD treatment, prediction of treatment response can significantly contribute to selecting the right treatment for the right patient. [Extracted from the article]

The article offers a study predicting disease severity in atopic dermatitis (AD) patients treated with cyclosporin A (CsA). Topics include patients with AD, treated with CsA were included; assessed by Eczema Area and Severity Index (EASI) and serum collected before start of CsA; study showed two patients have notable discrepancies between EASI and predicted EASI scores; and study demonstrates that p‐EASI consisting on serum biomarkers predicts disease severity in AD patients.

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers Keywords: atopic dermatitis; biologics; biomarkers EN atopic dermatitis biologics biomarkers 3287 3289 3 12/03/20 20201201 NES 201201 During the past decade, new more targeted therapies for the treatment of atopic dermatitis (AD) have been developed and are currently under investigation in clinical trials. As few patients did show a quick drop in sIL-2R, extending the current model to a larger patient population including different phenotypes of AD might identify subtypes of AD patients in whom sIL-2R is an important marker. [Extracted from the article]